Connecting the dots...Provectus Biopharmaceuticals: $PVCT.OB: Playing The Oldies

October 24, 2012

$PVCT.OB: Playing The Oldies

At 2010 ASCO, Adam Feuerstein conducted a live online chat at the conference during which he addressed Provectus after viewing their poster. The relevant portions from the chat are below.

Craig's abstract and poster will be presented at the SITC 27th Annual Meeting this weekend. I am very much looking forward to learning what data and information is on the poster. I hope we learn more about:

His bystander mechanism of action work in mice, which should parallell or foreshadow Moffitt's work and their results yet to be released,
Others cancers to which he has applied PV-10 besides melanoma, which should again foreshadow Moffitt, and
Combinational therapies involving PV-10, particularly for very late stage disease and heavy tumor burden.

No comments:

Post a Comment

Disclaimer

This blog is neither intended to be nor is investment advice. The author of this blog (the "Author") is not a registered investment advisor. Under no circumstances should any content from this blog be used or interpreted as a recommendation of a trade or investment in Provectus Biopharmaceuticals, Inc. Trading and investing can be hazardous to your wealth, health or both. Any investment decision must, in all cases and without exception, be made by the reader or by his or her registered investment advisor. This blog is only and strictly for educational and informational purposes. The Author may have a position in Provectus Biopharmaceuticals, Inc. at any given time that is not disclosed at the time of publication. All opinions expressed by the Author are subject to change without notice. You, the reader, should always obtain current information and perform the appropriate due diligence before making any investment or trading decision. All efforts are made to ensure the information contained in the blog and/or a blog post is factual and accurate; however, the Author does not guarantee its accuracy under any circumstances.

♢ Note: Provectus' board of directors appointed the Author as a special adviser to the board in February 2017. See the blog's Disclosures page.

♢♢ Note: The Author and others entered into a securities transaction with Provectus. See the blog's Disclosures page.